2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Infectious Diseases, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, APL, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5107 Allogeneic HSCT overcomes the poor prognosis of KMT2A-rearranged AML: The pivotal role of achieving MRD negativity

Yi Chen, Zhiwei Ding2, Nainong Li, MD3, Jing Zheng4
1 Fujian Medical University Union Hospital, fuzhou, China
2 Fujian Medical University Union Hospital, fuzhou, China
3 Fujian Medical University Union Hospital, fuzhou, China
4 Fujian Medical University Union Hospital, fuzhou, China

Background: KMT2A rearrangements (KMT2A-r) define a distinct subgroup of acute myeloid leukemia (AML) associated with adverse prognosis. Data on the clinical features, optimal initial therapy, and the prognostic impact of measurable residual disease (MRD) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in this population remain limited.

Methods: We retrospectively analyzed 155 adult patients with newly diagnosed KMT2A-r AML treated at our center. Clinical and molecular characteristics, treatment responses, relapse, and survival outcomes were evaluated.

Results: The cohort included 78 males and 77 females, with a median age of 48 years (range, 14-79). Median white blood cell count, hemoglobin, and platelet count at diagnosis were 13.0 × 10?/L, 73 g/L, and 45 × 10?/L, respectively. The most common KMT2A fusion partners were KMT2A-PTD (n=65), KMT2A::MLLT3 (n=38), KMT2A::ELL (n=19), and KMT2A::MLLT4 (n=18). Frequent co-occurring mutations included FLT3 (31.6%), IDH1/2 (14.2%), ASXL1 (12.9%), DNMT3A (12.9%), NRAS (11.6%), KRAS (11.0%), and RUNX1 (9.0%). Of 153 patients receiving antileukemic therapy, 114 received intensive 3+7 chemotherapy (IC), 23 received venetoclax plus azacitidine (VA), and 16 received other regimens. The overall complete remission (CR) rate after initial induction was 68.5%, with comparable rates between the IC and VA groups (72.8% vs. 75.0%, P>0.9999). Among patients achieving CR, relapse was frequent, with a median relapse time of 11.9 months; 1-, 3-, and 5-year relapse-free survival (RFS) were 49.9%, 37.5%, and 35.9%, respectively. The median overall survival (OS) for the entire cohort was 18.8 months, with 1-, 3-, and 5-year OS rates of 59.6%, 36.0%, and 30.8%. Patients who underwent allo-HSCT had significantly better OS than those who did not (median OS: not reached vs. 9.0 months, P<0.0001). Achieving gene-based MRD negativity was the most important favorable prognostic factor; MRD-negative patients had a median OS not reached compared to 8.8 months for MRD-positive patients (P<0.0001). Notably, 80.4% of transplanted patients achieved gene MRD negativity, compared to only 15.0% of non-transplanted patients (P<0.0001).

Conclusions: In this large cohort of adults with KMT2A-r AML, initial induction with intensive chemotherapy and venetoclax-based regimens yielded similar CR rates. However, relapse rates were high, and long-term survival remained poor. Allo-HSCT significantly improved survival, largely by facilitating the achievement of gene-based MRD negativity, which was the strongest predictor of favorable outcome. These findings underscore the importance of early MRD assessment and transplantation in this high-risk AML subgroup.

Nainong Li, MD: No relevant conflicts of interest to declare.